Drug Type Biosimilar, Monoclonal antibody |
Synonyms Hervycta |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date IN (26 Jul 2018), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Breast Cancer | IN | 26 Jul 2018 |